Treating Inadequately Controlled Asthma: Exploring the Potential of Phenotype-Targeted Therapy

Chairperson:

Mario Castro¹

Speakers:

Ratko Djukanovic,² Michael Wechsler³

1. Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
2. Southampton NIHR Respiratory Biomedical Research Unit, Southampton, UK
3. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine,
National Jewish Health, Denver, Colorado, USA

Disclosure:

Mario Castro has received research support from NIH, ALA, CDC, Amgen, Boston Scientific, Boehringer Ingelheim, Cephalon, Genentech, GSK, Invion, Johnson & Johnson, Kalobios, MedImmune, NextBio, Novartis, Sanofi Aventis, and Vectura. He is on the lecture bureau for Boehringer Ingelheim, Boston Scientific, Genentech, GSK, and Teva. He has acted as consultant for Boston Scientific, Galera, Genentech, GSK (DSMC), Holaira, MEDA, and Neostem. He holds stock in Sparo Labs. Ratko Djukanovic has acted as consultant for Teva, Novartis, Merck, Boehringer Ingelheim, and Synairgen. Michael Wechsler has provided consulting services to the following companies: Teva, GSK, Genentech, Boston Scientific, Novartis, Merck, AstraZeneca, and Boehringer Ingelheim.

Acknowledgements:

Writing assistance was provided by Dr Tabasum Mughal, ApotheCom.

Support:

The publication of this article was funded by Teva Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Teva Pharmaceuticals.

Citation:

EMJ Respir. 2015;3[2]:42-48. DOI/10.33590/emjrespir/10312229. https://doi.org/10.33590/emjrespir/10312229.

Keywords:

ERS Congress, European Respiratory Congress

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.